| pubmed-article:8166320 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8166320 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:8166320 | lifeskim:mentions | umls-concept:C0013227 | lld:lifeskim |
| pubmed-article:8166320 | lifeskim:mentions | umls-concept:C0004933 | lld:lifeskim |
| pubmed-article:8166320 | lifeskim:mentions | umls-concept:C2698651 | lld:lifeskim |
| pubmed-article:8166320 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:8166320 | pubmed:dateCreated | 1994-5-25 | lld:pubmed |
| pubmed-article:8166320 | pubmed:abstractText | Thirteen treatment-refractory schizophrenic patients (10 men and three women) who were receiving more than 50 mg/day of haloperidol and who had been hospitalized for more than 1 year successfully tolerated a mean dose reduction of 63% with consequent improvement in psychopathology and side effects. The addition of intensive behavior therapy to the optimal dose of haloperidol yielded further improvements in functional behavior, such as self-care and social interaction. | lld:pubmed |
| pubmed-article:8166320 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8166320 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8166320 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:8166320 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8166320 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8166320 | pubmed:month | May | lld:pubmed |
| pubmed-article:8166320 | pubmed:issn | 0002-953X | lld:pubmed |
| pubmed-article:8166320 | pubmed:author | pubmed-author:Van PuttenTT | lld:pubmed |
| pubmed-article:8166320 | pubmed:author | pubmed-author:MintzJJ | lld:pubmed |
| pubmed-article:8166320 | pubmed:author | pubmed-author:LibermanR PRP | lld:pubmed |
| pubmed-article:8166320 | pubmed:author | pubmed-author:MarderS RSR | lld:pubmed |
| pubmed-article:8166320 | pubmed:author | pubmed-author:MarshallB... | lld:pubmed |
| pubmed-article:8166320 | pubmed:author | pubmed-author:BowesGG | lld:pubmed |
| pubmed-article:8166320 | pubmed:author | pubmed-author:KuehnelT GTG | lld:pubmed |
| pubmed-article:8166320 | pubmed:author | pubmed-author:AravagiriMM | lld:pubmed |
| pubmed-article:8166320 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8166320 | pubmed:volume | 151 | lld:pubmed |
| pubmed-article:8166320 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8166320 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8166320 | pubmed:pagination | 756-9 | lld:pubmed |
| pubmed-article:8166320 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:8166320 | pubmed:meshHeading | pubmed-meshheading:8166320-... | lld:pubmed |
| pubmed-article:8166320 | pubmed:meshHeading | pubmed-meshheading:8166320-... | lld:pubmed |
| pubmed-article:8166320 | pubmed:meshHeading | pubmed-meshheading:8166320-... | lld:pubmed |
| pubmed-article:8166320 | pubmed:meshHeading | pubmed-meshheading:8166320-... | lld:pubmed |
| pubmed-article:8166320 | pubmed:meshHeading | pubmed-meshheading:8166320-... | lld:pubmed |
| pubmed-article:8166320 | pubmed:meshHeading | pubmed-meshheading:8166320-... | lld:pubmed |
| pubmed-article:8166320 | pubmed:meshHeading | pubmed-meshheading:8166320-... | lld:pubmed |
| pubmed-article:8166320 | pubmed:meshHeading | pubmed-meshheading:8166320-... | lld:pubmed |
| pubmed-article:8166320 | pubmed:meshHeading | pubmed-meshheading:8166320-... | lld:pubmed |
| pubmed-article:8166320 | pubmed:meshHeading | pubmed-meshheading:8166320-... | lld:pubmed |
| pubmed-article:8166320 | pubmed:meshHeading | pubmed-meshheading:8166320-... | lld:pubmed |
| pubmed-article:8166320 | pubmed:meshHeading | pubmed-meshheading:8166320-... | lld:pubmed |
| pubmed-article:8166320 | pubmed:meshHeading | pubmed-meshheading:8166320-... | lld:pubmed |
| pubmed-article:8166320 | pubmed:meshHeading | pubmed-meshheading:8166320-... | lld:pubmed |
| pubmed-article:8166320 | pubmed:year | 1994 | lld:pubmed |
| pubmed-article:8166320 | pubmed:articleTitle | Optimal drug and behavior therapy for treatment-refractory schizophrenic patients. | lld:pubmed |
| pubmed-article:8166320 | pubmed:affiliation | Camarillo-UCLA Research Center, Camarillo State Hospital, CA 93011-6022. | lld:pubmed |
| pubmed-article:8166320 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8166320 | lld:pubmed |
